Join us   Log in  

PHARMASPIRE - Volume 14,Issue 1 ,2022 , January-March 2022

Pages: 47-58
Print Article   Download XML  Download PDF

Exploring the potential of neuronutraceuticals as alternatives in the prevention of Alzheimer’s disease

Author: Ankur Kumar, Rouchan Ali, Ram Kumar, Pooja A. Chawla

Category: Pharmaceutics


Various chemical compounds with natural dietary origins have been shown to protect against age-related disorders, such as neurodegenerative diseases such as Alzheimer’s disease (AD). Such substances are known as nutraceuticals, and they differ structurally, function at distinct biochemical and metabolic levels, and have various neuroprotective characteristics. In this review, we analyzed the evidence from explanatory studies on the effects of selected nutritional supplements on age-related cognitive decline and dementia in humans, randomized clinical trials, and clinical trials. We provide findings from research on vitamins, flavonoids, and other natural compounds that have been researched in AD and may be useful for maintaining excellent cognitive function. In dementia-related therapy, nutraceuticals are not a choice due to a severe absence of high-quality research studies. Despite this, the significant potential for their neuroprotective effects discourages future research.

Keywords: Alzheimer’s disease, Cognitive impairment, Dementia, Dietary natural substances, Neurodegeneration, Nutraceuticals, Vitamins and minerals

DOI: 10.56933/Pharmaspire.2022.14106



1. Singh P, Sivanandam TM, Konar A, Thakur MK. Role of nutraceuticals in cognition during aging and related
disorders. Neurochem Int 2021;143:104928.
2. Zareen A, Rahman A. Nutraceuticals neuroprotect naturally: Alzheimer’s disease, Parkinson’s disease, stroke, and major depressive disorder. In: Studies in Natural Products Chemistry. Amsterdam, Netherlands: Elsevier; 2016. p. 373-97.
3. Govindarajulu M, Ramesh S, Neel L, Fabbrini M, Buabeid M, Fujihashi A, et al. Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer’s disease. Neurochem Int 2021;144:104958.
4. Calfio C, Gonzalez A, Singh SK, Rojo LE, MacCioni RB. The emerging role of nutraceuticals and phytochemicals in the prevention and treatment of Alzheimer’s disease. J Alzheimers Dis 2020;77:33-51.
5. Lokhande SS. Role of nutraceuticals in various diseases: A comprehensive review. Asian J Pharm Res 2018;8:236-40.
6. Carrasco-Gallardo C, Farías GA, Fuentes P, Crespo F, Maccioni RB. Can nutraceuticals prevent Alzheimer’s disease? Potential therapeutic role of a formulation containing shilajit and complex B Vitamins. Arch Med Res 2012;43:699-704.
7. Fisher AE, Naughton DP. Why nutraceuticals do not prevent or treat Alzheimer’s disease. Nutr J 2005;4:14. Kumar, et al.: Neuro-nutraceuticals in the prevention of Alzheimer’s disease 57 Pharmaspire | Vol. 14 | No. 1 | 2022
8. Sadhukhan P, Saha S, Dutta S, Mahalanobish S, Sil PC. Nutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer’s disease. Pharmacol Res 2018;129:100-14.
9. Farías GA, Guzmán-Martínez L, Delgado C, Maccioni RB. Nutraceuticals: A novel concept in prevention and treatment of Alzheimer’s disease and related disorders. J Alzheimers Dis 2014;42:357-67.
10. Rajam RP, Murugesan G, Vadivelkumar K, Menachisundaram V. Nutraceuticals a review. World J Pharm Res 1354-74.
11. Makkar R, Behl T, Bungau S, Zengin G, Mehta V, Kumar A, et al. Nutraceuticals in neurological disorders. Int J Mol Sci 2020;921:1-19.
12. Silvestri R. Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer’s disease. Med Res Rev 2009;29:295-338.
13. Taslimi P, Sujayev A, Turkan F, Garibov E, Huyut Z, Farzaliyev V, et al. Synthesis and investigation of the conversion reactions of pyrimidine-thiones with nucleophilic reagent and evaluation of their acetylcholinesterase, carbonic anhydrase inhibition, and antioxidant activities. J Biochem Mol Toxicol 2018;32:?e22019.
14. Lan JS, Ding Y, Liu Y, Kang P, Hou JW, Zhang XY, et al. Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer’s disease. Eur J Med Chem 2017;139:48-59.
15. Tarazi H, Odeh RA, Al-Qawasmeh R, Yousef IA, Voelter W, Al-Tel TH. Design, synthesis and SAR analysis of potent BACE1 inhibitors: Possible lead drug candidates for Alzheimer’s disease. Eur J Med Chem 2017;125:1213-24.
16. Ding C, Tian Q, Li J, Jiao M, Song S, Wang Y, et al. structural modification of natural product tanshinone leading to discovery of novel nitrogen-enriched derivatives with enhanced anticancer profile and improved drug-like properties. J Med Chem 2018;61:760-76.
17. Reddy EK, Remya C, Mantosh K, Sajith AM, Omkumar RV, Sadasivan C, et al. Novel tacrine derivatives exhibiting improved acetylcholinesterase inhibition: Design, synthesis and biological evaluation. Eur J Med Chem 2017;139:367-77.
18. Lefin R, van der Walt MM, Milne PJ, Terre’Blanche G. Imidazo[1,2-α]pyridines possess adenosine a1 receptor affinity for the potential treatment of cognition in neurological disorders. Bioorg Med Chem Lett
19. de Candia M, Zaetta G, Denora N, Tricarico D, Majellaro M, Cellamare S, et al. New azepino[4,3-b] Indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity. Eur J Med Chem
20. Lim JW, Kim SK, Choi SY, Kim DH, Gadhe CG, Lee HN, et al. Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer’s disease. Eur J Med Chem 2018;157:405-22.
21. Yazdani M, Edraki N, Badri R, Khoshneviszadeh M, Iraji A, Firuzi O. Multi-target inhibitors against alzheimer disease derived from 3-hydrazinyl 1,2,4-triazine scaffold containing pendant phenoxy methyl-1,2,3-triazole: Design, synthesis and biological evaluation. Bioorg Chem 2019;84:363-71.
22. Sadashiva CT, Chandra JN, Kavitha CV, Thimmegowda A, Subhash MN, Rangappa KS. Synthesis and pharmacological evaluation of novel N-alkyl/ aryl substituted thiazolidinone arecoline analogues as muscarinic receptor 1 agonist in Alzheimer’s dementia models. Eur J Med Chem 2009;44:4848-54.
23. Bilgicli HG, Taslimi P, Akyuz B, Tuzun B, Gulcin ?. Synthesis, characterization, biological evaluation, and molecular docking studies of some piperonyl-based 4-thiazolidinone derivatives. Arch Pharm (Weinheim) 2020;353:e1900304.
24. Jameel E, Meena P, Maqbool M, Kumar J, Ahmed W, Mumtazuddin S, et al. Rational design, synthesis and biological screening of triazine triazolopyrimidine hybrids as multitarget anti-Alzheimer agents. Eur J Med Chem 2017;136:36-51.
25. Iraji A, Firuzi O, Khoshneviszadeh M, Nadri H, Edraki N, Miri R. Synthesis and structure-activity relationship study of multi-target triazine derivatives as innovative candidates for treatment of Alzheimer’s disease. Bioorg Chem 2018;77:223-35.
26. Trifunovi? J, Bor?i? V, Vukmirovi? S, Mikov M. Assessment of the pharmacokinetic profile of novel s-triazine derivatives and their potential use in treatment of Alzheimer’s disease. Life Sci 2017;168:1-6.
27. Poliseno V, Chaves S, Brunetti L, Loiodice F, Carrieri A, Laghezza A, et al. Derivatives of tenuazonic acid as potential new multi-target anti-Alzheimer’s disease agents. Biomolecules 2021;11:1-23.
28. Li X, Yu Y, Tu Z. Pyrazole scaffold synthesis, functionalization, and applications in Alzheimer’s disease and Parkinson’s disease treatment (2011-2020). Molecules 2021;26:1202.
29. Aggarwal N, Jain S, Chopra N. Hybrids of thiazolidin- 4-ones and 1,3,4-thiadiazole: Synthesis and biological screening of a potential new class of acetylcholinesterae inhibitors. Biointerface Res Appl Chem 2022;12:2800-12.
30. Taslimi P, Turhan K, Türkan F, Karaman HS, Turgut Z, Gulcin ?. Cholinesterases, α-glycosidase, and carbonic anhydrase inhibition properties of 1H-pyrazolo[1,2-b] phthalazine-5,10-dione derivatives: Synthetic analogues for the treatment of Alzheimer’s disease and diabetes mellitus. Bioorg Chem 2020;97:103647.
31. Zaiter J, Hibot A, Hafid A, Khouili M, Neves CM,Simões MM, et al. Evaluation of the cellular protection
by novel spiropyrazole compounds in dopaminergic cell death. Eur J Med Chem 2021;213:113140.
32. Williams RJ, Mohanakumar KP, Beart PM. Neuronutraceuticals: Further insights into their promise for brain health. Neurochem Int 2016;95:1-3.
33. Chandra JN, Malviya M, Sadashiva CT, Subhash MN, Rangappa KS. Effect of novel arecoline thiazolidinones
as muscarinic receptor 1 agonist in Alzheimer’s dementia Kumar, et al.: Neuro-nutraceuticals in the prevention of Alzheimer’s disease Pharmaspire | Vol. 14 | No. 1 | 2022 58 models. Neurochem Int 2008;52:376-83.
34. Davinelli S, Calabrese V, Zella D, Scapagnini G. Epigenetic nutraceutical diets in Alzheimer’s disease. J Nutr Health Aging 2014;9:800-5. 35. Mecocci P, Tinarelli C, Schulz RJ, Polidori MC. Nutraceuticals in cognitive impairment and Alzheimer’s disease. Front Pharmacol 2014;5:147.
36. Gruendler R, Hippe B, Jengic VS, Peterlin B, Haslberger AG. Nutraceutical approaches of autophagy and neuroinflammation in Alzheimer’s disease: A systematic review. Molecules 2020;25:6018.
37. Sawikr Y, Yarla NS, Peluso I, Kamal MA, Aliev G, Bishayee A. Neuroinflammation in Alzheimer’s disease: The preventive and therapeutic potential of polyphenolic nutraceuticals. Adv Protein Chem Struct Biol 2017;108:33-57.
38. Ooi KL, Vacy K, Boon WC. Fatty acids and beyond: Age and Alzheimer’s disease related changes in lipids reveal the neuro-nutraceutical potential of lipids in cognition. Neurochem Int 2021;149:105143.
39. Guzman-Martinez L, Calfío C, Farias GA, Vilches C, Prieto R, Maccioni RB. New frontiers in the prevention, diagnosis, and treatment of Alzheimer’s disease. J Alzheimers Dis 2021;82:51-63.
40. Remington R, Bechtel C, Larsen D, Samar A, Page R, Morrell C, et al. Maintenance of cognitive performance and mood for individuals with Alzheimer’s disease following consumption of a nutraceutical formulation: A one-year, open-label study. J Alzheimers Dis 2016;51:991-5.
41. Ajjawi I, Shintani D. Engineered plants with elevated Vitamin E: A nutraceutical success story. Trends Biotechnol 2004;22:104-7.
42. Guzman-Martinez L, Farías GA, Tapia JP, Sánchez MP, Fuentes P, Gloger S, et al. Interventional study to evaluate the clinical effects and safety of the nutraceutical compound brainUp-10® in a cohort of patients with Alzheimer’s disease: A multicenter, randomized, doubleblind, and placebo controlled trial. J Alzheimers Dis 2021;81:1231-41.
43. Ahmed HH, Shousha WG, Hussien R, Farrag AR. Potential role of some nutraceuticals in the regression of Alzheimer’s disease in an experimental animal model. Turk J Med Sci 2011;41:455-66.
44. Ashwini GC, Vaishali SK, Ram SS, Ganesh OB, Digambar NN. Role of nutraceuticals in various diseases: A comprehensive review. Int J Res Pharm Chem 2013;3:290-9.
45. Douraghi-Zadeh D, Matharu B, Razvi A, Austen B. The protective effects of the nutraceutical, colostrinin, against Alzheimer’s disease, is mediated via prevention of apoptosis in human neurones induced by aggregated β-amyloid. J Nutr Health Aging 2009;13:522-7.
46. Ghai R, Nagarajan K, Arora M, Grover P, Ali N, Kapoor G. Current strategies and novel drug approaches for Alzheimer disease. CNS Neurol Disord Drug Targets 2020;19:676-90.
47. Kelsey NA, Wilkins HM, Linseman DA. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010;15:7792-814.
48. Amat-ur-Rasool H, Symes F, Tooth D, Schaffert LN, Elmorsy E, Ahmed M, et al. Potential nutraceutical properties of leaves from several commonly cultivated plants. Biomolecules 2020;10:1556.
49. Maccioni RB, Calfío C, González A, Lüttges V. Novel nutraceutical compounds in Alzheimer prevention. Biomolecules 2022;12:249.
50. Ahmad SS, Khalid M, Kamal MA, Younis K. Study of nutraceuticals and phytochemicals for the management of Alzheimer’s disease: A review. Curr Neuropharmacol 2021;19:1884-95.
51. Sun GY, Simonyi A, Fritsche KL, Chuang DY, Hannink M, Gu Z, et al. Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases. Prostaglandins Leukot Essent Fatty Acids 2018;136:3-13.
52. Mori T, Koyama N, Guillot-Sestier MV, Tan J, Town T. Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. PLoS One 2013;8:55774.
53. Nasri H, Baradaran A, Shirzad H, Rafieian-Kopaei M. New concepts in nutraceuticals as alternative for pharmaceuticals. Int J Prev Med 2014;5:1487.
54. Frisardi V, Panza F, Seripa D, Imbimbo BP, Vendemiale G, Pilotto A, et al. Nutraceutical properties of Mediterranean diet and cognitive decline: Possible underlying mechanisms. J Alzheimers Dis 2010;22:715-40.
55. Rajasekaran A, Sivagnanam G, Xavier R. Nutraceuticals as therapeutic agents: A Review. Res J Pharm Technol 2008;1:328-40.
56. Geetha PS, Kanchana S, Pasupathi E, Murugan M, Rohini C. A review on putative mechanism of action of nootropic herb Bacopa monnieri. Pharm Innov J 2021;11:4-5.
57. Gregory J, Vengalasetti YV, Bredesen DE, Rao RV. Neuroprotective herbs for the management of Alzheimer’s disease. Biomolecules 2021;11:543.
58. Orhan IE. Centella asiatica (L.) Urban: From traditional medicine to modern medicine with neuroprotective potential. Evid Based Complement Alternat Med
59. Dutta S, Ali KM, Dash SK, Giri B. Role of nutraceuticals on health promotion and disease prevention: A review. J Drug Deliv Ther 2018;8:42-7.